home All News open_in_new Full Article

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial – – Halneuron® CINP P2b study interim data readout is expected in Q4 2025 – – Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward – – Capital raise provides operational runway through […]


today 3 d. ago attach_file Culture

attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Other
attach_file Culture
attach_file Society
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture


ID: 3581970097
Add Watch Country

arrow_drop_down